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SUMMARY
This article reviewed the current state of the art in head and neck oncology. 
These include very important and stimulating new areas of interest including 
the marked acceptance of  chemoradiation in favor of surgery in patients with 
cancer of the head and neck. The concept of HPV as a cause of cancer of 
the  oropharynx is relatively new and very important in the epidemiology of 
these tumors. New modalities such as PET CT scanning and robotic surgery 
are discussed and appear to be very important in management of cancer of 
the head and neck. Endoscopic endonasal skull base surgery is another new 
high technology contribution to the ﬁ eld of head and neck surgery as is the 
use of endoscopic assisted thyroid surgery. These and other new concepts 
are discussed in this manuscript.
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Introduction
Squamous cell carcinoma is the most common cancer 
arising in the head and neck and affects more than 
500,000 patients each year world wide. It has been 
thought that these cancers arise in the mucosa after 
exposure to carcinogens such as tobacco and alco-
hol. Recently, however, the human papilloma virus 
(HPV) has been strongly implicated as a causative 
agent particularly in cancer of the oropharynx. The 
complex regional anatomy and vital physiological role 
of the structures involved dictate that the goals of 
treatment are not only to attempt to cure the cancer, 
but also to preserve function. A multidisciplinary ap-
proach is important in treating these patients given 
the complexity of treatment and acute and long term 
complications that result from chemotherapy, radia-
tion therapy and surgery. Appropriate clinical and 
radiographic staging is crucial for accurate treatment 
planning and delivery [1]. 
The pendulum has swung away from primary surgery 
to chemoradiation with surgery left for the salvage of 
therapeutic failures. The development of PET CT scanning 
has proven invaluable, both for initial precise staging of 
the cancer and follow up after chemoradiation. Molecular 
targeting agents, particularly epidermal growth factor 
inhibitors, have been successfully integrated into poten-
tially curative treatment of locally advanced squamous 
cell carcinoma of the head and neck [2]. 
Recently, major improvements in technology includ-
ing microvascular reconstruction, technical advances 
in radiation therapy delivery, such as IMRT and cyber 
knife, transoral laser therapy for cancer of the base of 
the tongue and larynx,and robotic surgery for cancer 
of the oropharynx and larynx have lead to improve-
ment in patient care.
HPV has been shown to cause virtually all cancers 
of the female cervix. Molecular evidence also suggests 
a role for HPV particularly HPV 16 in the pathogenesis 
of a subgroup of squamous cell carcinomas in the head 
and neck. HPV DNA was detected in 72% of 100 oro-
pharynx tumor specimens and 64% of the patients in 
the study were sero-positive for HPV 16 E6, HPV16 E7 
or both [3]. Furthermore, exposure to HPV increased 
the association with cancer of the oropharyngeal re-
gardless of the use of tobacco or alcohol and without 
evidence of synergy between exposure to HPV and the 
use of tobacco and alcohol. These data suggest that 
two distinct pathways may be involved in the develop-
ment of cancer of the oropharynx. One may be driven 
by tobacco and alcohol and the other by HPV induced 
genetic instability. 
Among young patients, widespread use of oral 
sexual practices and a trend towards multiple sexual 
partners may be contributing to an increased incidence 
of HPV related head and neck cancer particularly 
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those in the tonsil and base of the tongue. In fact, in 
Stockholm a recent report disclosed that between 1970 
and 2002 there was a threefold parallel increase in 
the incidence of squamous cell carcinoma of the oro-
pharynx and the proportion of HPV positive squamous 
cell carcinoma. The authors stated that “the incidence 
of HPV positive tonsil cancer is still increasing in the 
county of Stockholm suggesting an epidemic of virus 
induced cancer with soon almost all tonsil cancer be-
ing HPV positive, as in cervical cancer [4]. Since HPV 
vaccination is an important strategy to prevent cervical 
cancer, so it would seem logical that HPV vaccination 
trials may be tested as a potential means of preventing 
HPV induced cancer of the head and neck.
Advances in treatment strategies have affected all 
the approaches used in head and neck cancer: radiation 
therapy, chemotherapy, and targeted agents: radiation 
therapy is now the mainstay of curative therapy for 
oropharyngeal cancer and advanced hypopharyngeal 
and laryngeal cancer. Recent advances have focused 
primarily on variations in fractionation schedule and 
intensity modulated radiation therapy (IMRT) a form 
of high precision conformal radiotherapy that delivers 
radiation more precisely to the tumor while relatively 
sparing the surrounding normal tissue in particular 
the salivary glands to try to prevent xerostomia. In our 
Department and others, the cyberknife has come into 
common practice for use in patients with recurrent 
cancer in the head and neck. 
Chemotherapy is an integral part of treating locally 
advanced head and neck cancer. It may be administered 
either before radiotherapy as induction (neoadjuvant) 
therapy or concurrently with radiotherapy. Postopera-
tive adjunctive chemoradiation continues to play an 
important role in treating locally advanced, but oper-
able, cancer of the head and neck [5, 6]. 
Targeting agents such as Cetuximab appear to have 
promise both in combination with chemo/radiotherapy 
as primary treatment, or as single agents in patients 
with recurrent or metastatic cancer [7, 8]. 
Nonsurgical treatment
Concurrent chemotherapy has a long record of im-
proving local and regional control in squamous cell 
carcinoma of the head and neck, however, its affect 
on distant metastases is controversial. Conversely 
induction chemotherapy appears to reduce distant 
metastases. Induction chemotherapy may be ideally 
used in patients with good performance status and 
advanced primary and nodal presentations, such as 
T3, T4, and N2A or N3. It is also reasonable to offer 
induction chemotherapy to symptomatic patients in 
need of immediate therapy. 
Many retrospective analyses have shown poor out-
come for patients with squamous cell carcinoma of the 
head and neck which express high levels of EGFR. 
Targeting this receptor with a monoclonal antibody has 
been successfully exploited for therapeutic purposes, 
an example of which previousy mentioned is cetuximab. 
Cetuximab is a monoclonal antibody approved by the 
FDA for treating cancer of the head and neck. Its use 
as a single agent in patients with platinum resistant 
cancer has been approved for use in combination with 
radiation in previously untreated patients. Bonner et 
al [7], in a recent Phase III trial, demonstrated that 
cetuximab in combination with radiotherapy improved 
local regional control and progression free and overall 
survival in locally advanced cancer. Treatment with 
a combination regimen decreased the risk of local 
regional progression by 32% and the risk of death by 
26%. However, the rates of distant metastasis in one 
and two years were similar in the two study groups. 
Cetuximab has also been tested as a single agent in 
103 patients with recurrent or metastatic head and 
neck cancer resistant to platinum based therapy. The 
response rate was 13% and the rate of cancer control 
was 46% [8]. 
Angiogenesis is also fundamental to cancer growth 
and metastasis and is regulated by many endogenous 
pro-angiogenic and anti-angiogenic factors, the most 
important being the vascular endothelial growth factor 
(VEGF) and its receptors [9]. VEGF can be upregu-
lated and has prognostic significance in squamous 
cell carcinoma of the head and neck. Anti-angiogenesis 
therapeutic strategies have been extensively studied 
in other solid tumors and are currently being evalu-
ated in the treatment of squamous cell carcinoma of 
the head and neck. 
Definitive chemoradiation for cancer of the orophar-
ynx, larynx, and hypopharynx has replaced surgery in 
many cases. A meta-analysis involving patients with 
head and neck cancer showed an absolute benefit of 
8% associated with concurrent chemoradiation com-
pared to radiation therapy alone [10]. Unfortunately the 
side effects of many of the chemotherapy approaches 
include neuropathy, hearing loss, marked nausea and 
vomiting, renal dysfunction and long term sequela 
such as dysphagia. 
Postoperative concurrent chemoradiation has been 
tested in two Phase III studies conducted by the Ra-
diation Therapy Oncology Group (RTOG) [5] and the 
European Organization for Research and Treatment 
of Cancer (EORTC) [6]. Both trials aimed to determine 
whether the addition of cisplatinum to radiotherapy 
improved the outcome as compared with radiotherapy 
alone. In both studies, patients with high risk patho-
logical features after surgery were randomly assigned 
to receive either radiotherapy alone or radiotherapy 
plus cisplatinum. High risk features were defined as 
the presence of positive margins, extracapsular spread, 
lymphovascular invasion, perineural invasion, and 
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multiple positive lymph nodes. In the RTOG study 
concurrent chemotherapy significantly reduced the risk 
of local regional recurrence compared with radiation 
therapy alone, but, unfortunately no benefit in survival 
was noted. In the EORTC study, both progression free 
survival and overall survival rates were significantly 
better in patients receiving concurrent chemoradiation. 
Both trials demonstrated that adding cisplatinum 
had no significant effect on the incidence of distant 
metastasis. Although postoperative concurrent chemo-
therapy was more effective than radiotherapy alone, it 
was also more toxic. 
Long term sequel of these nonsurgical treatments 
include:, dysphagia, osteo-radionecrosis, dental caries, 
trismus, thyroid dysfunction, sensorineural hearing 
loss, myelitis and pharyngeal or esophageal stenosis. 
Radiation induced xerostomia is a universal problem 
for long-term survivors. Unfortunately there is no radio-
protectant with proven efficacy available in decreasing 
the severity of mucositis during chemoradiation therapy 
for squamous cell carcinoma. 
Larynx
Several interesting trends have arisen in the treatment 
of laryngeal cancer since the landmark study conducted 
by the Veterans Affairs Laryngeal Cancer Study Group in 
1991. That study concluded that induction chemotherapy 
followed by radiation therapy for complete responders 
gave the same results as total laryngectomy followed 
by radiation therapy, but the chemoradiation survivors 
retained their larynx. This has evolved into treatment 
with concurrent chemoradiation (CR) based on the re-
sults of the Radiation Therapy Oncology Group (RTOG) 
trial 91-11 which showed improved local control rates. 
These clinical trials have impacted practice patterns 
as reflected in the National Cancer Database by an in-
crease in the use of chemoradiation in both community 
hospitals and academic centers [11]. 
Parodoxically during this same time period, survival 
amongst patients with laryngeal cancer had decreased 
according to the National Cancer Data Base (NCDB) [12]. 
The decreased survival parallels the observed trend of 
increasing use of nonoperative treatment in patients with 
laryngeal cancer. In contrast to results of the VA study 
an analysis of NCDB records of patients with laryngeal 
cancer found an increased risk of death for stage IV 
patients treated with chemoradiation [13] suggesting 
that there may be differences in patient populations and 
the application of treatment between the clinical trial 
setting and the larger community was analyzed. 
A total of 451 patients at the Medical College of 
Georgia who underwent primary surgical therapy in-
cluding cordectomy and partial horizontal laryngec-
tomy and total or extended total laryngectomy were 
included in this study with a mean follow up time 
of 35 months [14]. The authors demonstrated that 
nonoperative treatments were associated with poorer 
survival for patients with Stage IV cancer of the larynx 
and particularly a subset of patients with T4 cancer. 
T4 lesions are defined as tumors that invade through 
the thyroid cartilage or invade soft tissues beyond the 
larynx. Nodal status was associated with an increased 
risk of disease specific mortality in Stage IV disease. 
Only treatment was significant in the analysis of T4 
patients suggesting that T4 status may be the single 
most important predictor of survival differences be-
tween surgical and nonoperative treatment for patients 
with Stage IV laryngeal cancer. These data suggest that 
the observed national decrease in survival for laryngeal 
cancer may be due to the shift toward nonoperative 
treatment in the subset of patients with advanced 
laryngeal cancer. 
Early laryngeal cancer can be effectively treated 
either by larynx preserving surgery or with external 
beam radiation therapy or chemoradiation. Results in 
terms of tumor control and preservation of function 
for both modalities are satisfactory with reported rates 
of recurrence or persistence of tumor varying from 10 
to 35% [15]. However, if there is local recurrence after 
radiation therapy then surgery is mandatory and total 
laryngectomy remains the most frequently used tech-
nique for achieving local control. However, in selected 
cases, partial surgery with an attempt to preserve 
laryngeal function can be considered. 
Recent reports in the literature indicate that supra-
cricoid partial laryngectomy (SPL) is a valid alternative 
to total laryngectomy in selected cases of radiation 
failure. It can be a safe option oncologically and at 
the same time a valuable solution for retention of the 
all important functions of speaking and swallowing. 
The authors [15] describe a series of 31 patients who 
had failed treatment with radiation who were treated 
with SPL over a 20 year period. Historically, a total 
laryngectomy for salvage in cases of early laryngeal 
cancer failing radiation therapy achieves local control 
in 78 to 85% of T1 (preoperative staging) and 65% of 
T2 (preradiotherapy staging). Oncologic results with 
salvage SPL of 75% indicated that this operation is a 
serious alternative to total laryngectomy in carefully 
selected cases of radiation failure. 
Endoscopic horizontal partial laryngectomy, using 
a CO2 laser, is another conservation technique which 
has been found useful in the treatment of early cancer. 
Bussu et al [16] studied a series of 144 patients who 
underwent laser supraglottic partial laryngectomy as 
primary treatment for supraglottic squamous cell car-
cinoma. The authors state that a horizontal supraglottic 
laryngectomy is the mainstay of surgical management 
of the primary tumor for T1, T2 and selected T3 cancers 
of the supraglottic area producing good local control 
while allowing the patient to retain their voice. Unless 
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nodes are positive, Stage I and Stage II lesions could be 
treated by surgery as a single modality with a low rate 
of complications and good functionality saving radiation 
therapy for possible recurrence or a second primary 
tumor which occurs not infrequently. They cite the im-
portance of neck dissection in the overall management 
of these patients. The authors did not find a significant 
difference between the oncologic endpoints of the exter-
nal and the endoscopic approach. Following treatment of 
the primary, a selective neck dissection levels II, III and 
IV was carried out. The authors had a few recurrences in 
both the endoscopic group and the external horizontal 
laryngectomy group. They were able to perform a total 
laryngectomy successfully for salvage. 
Chen et al [17] studied the impact of the treating 
facilities volume of cases on survival for early stage 
laryngeal cancer to evaluate the relationship between 
total treatment volume of patients and survival in the 
first five years after treatment. Their analysis dem-
onstrated that for patients with early stage laryngeal 
cancer several factors are associated with survival 
including: type of treatment, volume of cases in the 
treating facility, and the patients’ insurance status. The 
report disclosed that patients with early stage laryngeal 
cancer treated initially with surgery had substantially 
better survival than those treated with radiation. 
This is the first study to report poor survival for 
patients treated with radiation as compared with sur-
gery and raises questions about the evidence base for 
including radiation and surgery as equally effective in 
treating early stage laryngeal cancer. The conclusion 
is based on 11.446 cases of early stage laryngeal can-
cer. The authors suggest that radiation treatment (vs. 
surgery) and treatment at low volume (vs. high volume) 
facilities are both associated with poor survival. They 
do not know whether the apparent lower survival in low 
volume facilities reflects understaging the primary la-
ryngeal cancer, patient selection factors, or poor quality 
of care. Patients who are uninsured or had Medicare, 
Medicaid or other types of government insurance had 
lower survival rates compared with those patients who 
had private insurance. It is most likely attributable to 
difficulties in access to primary specialty care amongst 
patients with no or inadequate insurance. 
Chen et al [18] found that black patients with la-
ryngeal cancer had a decreased likelihood of survival 
compared with whites even after controlling for clini-
cal factors, insurance types and area socioeconomic 
characteristics. A recent Canadian study also reported 
differences in cost specific survival for patients with 
laryngeal cancer based on socioeconomic status [19]. 
Oropharynx
The epidemiology, diagnosis, and treatment of oropha-
ryngeal cancers are in a state of transition. Although 
there are new imaging and screening methodologies 
making earlier diagnosis more accurate as well as new 
treatment modalities the clinical challenges for both 
patient and surgeon/physician remain essentially 
unchanged. Although there has been improved local 
regional control, this may not translate into improved 
overall survival. 
The vast majority of primary tumors of the oro-
pharynx are squamous cell carcinoma and the recent 
literature suggests that many of these are associ-
ated with human papilloma virus (HPV), a situation 
which may be more amenable to curative treatment 
[20]. Approximately 5,000 new cases of cancer of the 
oropharynx diagnosed in the United States annually 
have in the past been closely correlated with tobacco 
and alcohol abuse. In Western Europe and the United 
States recent studies suggest that there is an increased 
incidence of these cancers in people less than 45 years 
of age. Studies have shown an increased relative risk 
for cancer of the oropharynx in patients with HPV se-
ropositivity and HPV infection or both. This increased 
risk seems to be higher in younger populations and 
different patterns of sexual behaviors may partially 
account for this trend. Most HPV associated cancers 
originate in the tonsil for reasons not currently under-
stood. Although HPV 16 and 18 are associated with 
cancer of the female genital tract, the vast majority of 
HPV associated head and neck cancers are associated 
with HPV 16 only. The role of HPV vaccination in the 
prevention of cervical cancer suggests itself in cancer 
of the head and neck. 
The use of PET CT scanning appears to enhance 
the detection of primary cancers and cervical me-
tastasis in the oropharynx. This is important since 
many of these cancers present initially with a mass 
in the neck with no obvious primary site. PET CT is 
very helpful in identifying the primary cancer in the 
oropharynx in such cases so that these will no longer 
be considered metastatic to the neck from an “unknown 
primary cancer”. 
The paradigm has shifted in managing these pa-
tients and Cohan et al [20] recommend that all medi-
cally able patients with a biopsy proven cancer of the 
base of the tongue receive chemoradiation to their 
primary disease and the neck with neck dissection 
reserved for those patients that have initial N2 disease 
or greater. 
In our Department following chemoradiation: 1. if 
the physical examination is normal, the patients are 
followed with PET CT scans rather than planned post 
treatment neck dissections. 2. Patients with cancer of 
the posterior pharyngeal wall are offered chemoradia-
tion as a primary treatment modality reserving surgery 
for salvage therapy. 3. Early cancer of the soft palate is 
excised surgically. Patients with higher stage tumors 
will be offered adjuvant radiation therapy encompassing 
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the primary site and the retropharyngeal lymph nodes. 
4. The treatment of tonsil cancer remains a clinical 
treatment dilemma since there are no prospective ran-
domized studies or site specific retrospective analyses 
that clearly indicate which is the superior approach to 
this locally and regionally aggressive disease. Cohan’s 
patients are offered first-line therapy choices of chemo-
radiation with surgery for salvage or primary surgical 
resection with adjuvant chemoradiation.
Grant et al [21] reviewed a series of 206 patient 
swith cancer of the oropharynx who underwent tran-
soral laser microsurgery (TLM). They found that TLM 
alone with neck dissection is an effective approach for 
highly selected T1 to T3 N0 or N1 cancer of the oro-
pharynx. In this series the TLM control of the disease 
at the primary site was 66/69 patients. Those patients 
with local recurrence were successfully salvaged with 
further TLM. The overall local control rate was 94%. 
This is comparable with local control rates for con-
ventional surgery with or without adjuvant radiation 
therapy and for primary radiation therapy with or with-
out neck dissection [22]. The primary neck dissection 
was found to be an effective approach for the N0 and 
N1 and select N2 neck. Thirty-five of their 44 patients 
in the series had neck dissections. The authors state 
that TLM has considerable advantage over radiation 
therapy or concurrent CRT including chemoradiation 
therapy, including lower morbidity, short duration of 
treatment, and patient acceptance. This technique 
re-establishes the principle of primary surgery as it 
was in the open surgery era for acceptable local and 
regional disease control and to more accurately identify 
the requirement for adjuvant therapy. 
Henstrom et al [23] reported a series of 141 patients 
who underwent surgical resection for primary cancer 
of the base of the tongue. They reviewed the outcome of 
20 of these patients who underwent transoral resection 
with the use of the microscope and laser together with 
neck dissection with and without adjuvant therapy. 
Good results were based upon carefully assessing the 
site of neck metastasis, sampling the retropharyngeal 
nodes, dissecting both sides of the neck when there is 
palpable or radiographic suspected metastasis on the 
contralateral side and prescribing adjuvant therapy 
for a specific group of high risk patients. Maintain-
ing function is one of the outcome measures in these 
patients. The authors attribute their high function-
ality rates to performing selective or modified neck 
dissection, thus preserving the spinal accessory and 
sensory nerves. The authors feel that the surgical tech-
niques will continue to be improved and they believe 
that transoral resection will continue to be a superior 
option for patients with squamous cell carcinoma of 
the base of the tongue and it should be considered a 
real alternative to chemoradiation therapy for early 
primary cancer. 
Cano et al [24] reported a series of 88 patients 
with carcinoma of the base of the tongue treated with 
concurrent chemoradiation (50Gy) followed by brachy-
therapy. They found that this is a safe and effective 
method of treating squamous cell carcinoma of the 
base of the tongue. This protocol focused on organ 
preservation given the role of the base of the tongue 
in speech and swallowing function. This was a para-
digm shift in the management of patients with cancer 
of the oropharynx since prior to this study we used 
surgical resection with postoperative adjunctive radia-
tion therapy. Brachytherapy given both to the base 
of the tongue and to the neck for those patients who 
were node positive proved to be an effective method of 
directly boosting dose intensity to a particular target. 
The neck was treated with brachytherapy (25Gy) if it 
was cN+ at initial presentation. We found this approach 
to be extremely effective in controlling metastasis to 
the cervical lymph nodes and a neck dissection was 
performed only if there was residual disease follow-
ing brachytherapy or if regional metastasis recurred. 
Following chemoradiation and brachytherapy, only 6 
patients (6.8%) had a persistent or recurrent mass in 
the neck that was palpable or discovered on PET CT 
scanning. Neck dissection was performed in those 
patients and four specimens were found positive for 
tumor. Five of the six patients remain disease free. 
We have adopted the use of PET CT scan to monitor 
for local regional control following definitive chemora-
diation therapy. Our Department as well as others in 
the literature, have reported that a neck dissection can 
be deferred when clinical examination and PET scan 
findings are negative. The use of combined chemora-
diation with brachytherapy has lead to a high rate of 
local regional control with a low rate of short term or 
long term complications. The control rate was nearly 
80%, and our 5 to 7% rate of complications seems 
acceptable but demonstrates the technical expertise 
necessary in the placement of brachytherapy catheters. 
The substitution of brachytherapy catheters for exter-
nal beam radiation appears to decrease the severity of 
xerostomia, trismus and osteoradionecrosis providing 
improvement in the quality of life for these patients. 
Cancer of the nasopharynx (NPC)
Chevalier Jackson in 1901 published an article entitled 
“Primary Carcinoma of the Nasopharynx: Table of 
Cases” [25]. This created an awareness of this cancer 
in the United States for the first time. This tumor has 
a geographic prevalence in the Southeastern China 
province of Guangdong therefore being known as the 
“Chinese tumor”, but is also prevelant throughout 
Southeast Asia. The management of NPC was palliative 
in the early years before the introduction of radiation 
therapy. Curative treatment with long term survival 
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became possible only after the introduction of the linear 
accelerator in 1953. However, now with new types of 
imaging studies with more precise diagnosis, remark-
able improvements in radiation therapy techniques 
and chemotherapy, the management of this disease 
has improved dramatically. 
A randomized study with concurrent chemoradia-
tion and adjunctive chemotherapy was carried out at 
the Dana Farber Cancer Center in Boston. This study 
indicated significant improvement in a three year pro-
gression free survival from 24% vs. 69% and an overall 
survival of 47% vs. 78% compared with radiation alone. 
This study employed three courses of concurrent cis-
platinum with radiotherapy followed by three courses 
of adjuvant chemotherapy using cisplatinum and 5-FU. 
This trial has been considered a break -through in the 
use of chemotherapy for NPC [26].
Treatment of recurrent cancer in the nasopharynx 
is difficult but good results may be obtained using a 
variety of both standard and new techniques. Brachy-
therapy, which has been the standard treatment, deliv-
ers a high dose of radiation directly to the recurrent 
cancer which has the advantage of providing radiation 
at a continuous low-dose rate which may confer ad-
ditional radiobiological effectiveness compared to frac-
tionated external beam radiation. Yeo et al [27] studied 
a cohort of patients treated primarily with radiotherapy 
using supplemental intercavitary brachytherapy to 
boost the total dose to the nasopharynx and enhance 
local control. Their center used a protocol from 1996 to 
2000 that routinely used ICB (Interstitial Intercavitary 
Brachytherapy) to achieve the ICB boost for all T1/T2 
tumors treated with curative intent. The authors state 
that ICB is an effective and well tolerated procedure 
and is more economical than IMRT. 
Kim et al [28] suggest that intensely modulated 
radiation therapy (IMRT) with simultaneous integrated 
boost (SIB) technique following neoadjuvant chemo-
therapy for locally advanced nasopharyngeal carcinoma 
was feasible and effective for achieving local regional 
control in advanced cancers. The incorporation of 
neoadjuvant chemotherapy enables reduction in gross 
tumor volume. Using this approach it may be possible 
to reduce the dose to the normal structures and reduce 
radiation therapy related toxicity such as xerostomia 
without compromising treatment outcome. 
The use of surgical techniques to remove recurrent 
cancer of the nasopharynx have been well described 
and include splitting the soft palate followed by surgical 
resection. The problem with this technique was lack 
of good exposure. Dr. William Wei of Hong Kong [29] 
introduced the technique of open nasopharyngectomy 
using an osteotomy of the maxilla, allowing the maxilla 
to be displaced laterally while attached to a cheek flap 
which provided excellent exposure and after the resec-
tion of the recurrent tumor, the osteotomies were plated 
and the flap was sewn back in place. This resulted in a 
good five-year survival and excellent cosmetic results. 
Between February of ’89 and September ’99, the maxil-
lary swing nasopharyngectomy was employed by Dr. 
Wei as a surgical salvage procedure for 71 patients 
with recurrent or persistent primary NPC. In fifty-four 
patients resection resulted in a five-year actuarial local 
tumor control of 62% and a five-year actuarial survival 
of 49%. There is a great interest in treating recurrent 
local disease because otherwise, it always leads to the 
death of the patient. 
Ko and his colleagues [30] use the endoscopic KTP 
laser pharyngectomy which they state is a safe and 
simple procedure in treating T1 NPC. The technique 
included using a zero or 30° angle endoscope with 
the laser to get a clear resection margin down to and 
sometimes into the prevertebral muscles depending 
on the extent of tumor infiltration. There were few 
postoperative problems in this series of patients. Five 
patients underwent endoscopic nasopharyngectomy. 
The two-year local disease free rate for T1 tumor was 
100% and the two-year overall survival rate was 41.7%. 
The authors concluded that the endoscopic pharyngec-
tomy with KTP laser is a simple, safe, and successful 
procedure for treatment of recurrent T1 NPC. 
Tan et al [31] reported that Photo Dynamic Therapy 
(PDT) has the potential to be a very effective local treat-
ment modality for NPC without the severe side effects 
seen with radiation therapy. Clinical trials with either 
HpD or Photofrin has shown that PDT is effective in 
destroying NPC with good local control and a complete 
response in the majority of small recurrent or persis-
tent cancers (T1-2). Long term palliation in advanced 
stage (T3, T4) recurrence was also noted. Although 
these results were encouraging, PDT for NPC has not 
been considered as a breakthrough. It is felt that three 
issues are responsible for this fact: 
1. Reliable and reproducible light exposure has 
not been achieved since it is almost impossible to il-
luminate the whole tumor area with a lens fiber guided 
with an endoscope. 
2. The wave length of light used in these studies to 
activate HPD or Photofrin which are photosensitizers 
limits the depth of necrosis. 
3. The prolonged skin photosensitivity seen with 
these sensitizers which may last for 1-2 months re-
stricts the patients in their daily life.
FOSCAN, the second generation of photosensitizer 
approved in Europe for treatment of advanced cancer of 
the head and neck has the potential to be an efficient 
drug to treat NPC. Since the complex shape of the naso-
pharynx makes it impossible to produce a homogenous 
field of illumination, a new nasopharyngeal light ap-
plicator has been designed by the investigators. The ap-
plicator is introduced into the nasopharynx transorally 
attached to two guidance tubes inserted through the 
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nose and secured with a small silicone flange at the 
level of the nostrils. In a feasibility study conducted in 
Indonesia, the preliminary data for FOSCAN PDT in the 
nasopharynx are very promising. Eighteen (18) patients 
with recurrent or persistent NPC were treated in the 
study and only two recurrences were noted. One great 
advantage of the FOSCAN-PDT in NPC is the simplicity 
of the procedure and that it can be performed under 
local anesthesia. Another advantage is that it can 
be used for treatment of previously irradiated areas 
without the risk of excessive toxicity in normal tissue. 
Although PDT is a local treatment, this modality could 
be considered as part of the primary treatment for 
NPC. The authors feel that as a result of this study in 
Indonesia that the use of a single agent such as PDT in 
NPC with a N0 neck is a realistic alternative to radia-
tion therapy. This could reduce the treatment time of 
six weeks of daily fractionated radiation therapy for a 
few days of PDT treatment. 
Sentinel node biopsy
Sentinel node lymph node biopsy (SLNB) is a minimally 
to moderately invasive technique which allows the sur-
geon to identify, excise and meticulously examine the 
primary draining lymph nodes in a clinically N0 neck 
[32]. The use of SLNB in melanoma of the extremities 
and breast cancer is well established, however, it is 
still considered investigational for squamous cell car-
cinoma of the mucosal surface of the head and neck or 
for cutaneous squamous cell carcinoma or melanoma 
of the head and neck. Multiple centers in Europe have 
adopted SLNB as a standard additional approach to the 
neck for early clinically accessible mucosal squamous 
cell carcinoma. It provides accurate information and 
identifies those patients who may benefit from addi-
tional treatment to the cervical lymphatics. 
Civantos et al [32] reported on the clinical utility of 
SLNB of the head and neck in their own experience. An 
institutional validation study was recently completed 
which included 25 institutions and 34 certified sur-
geons under the general supervision of the American 
College of Surgeons Oncology Group. A total of 137 
evaluable patients were studied. As a result of this 
analysis, the authors concluded that multiple issues 
remain to be resolved before SLNB can be advocated 
as a reasonable alternative to selective neck dissection 
for the majority of early oral cancers. 
There is still significant true morbidity associated 
in selective neck dissection so that the use of SLNB, 
if validated, would be an intermediate option between 
observation alone and selective neck dissection. One 
problem is the inability to achieve immediate diagnosis 
of positive sentinel nodes because frozen section tech-
nique, even with multiple sections, is not sufficiently 
accurate [33]. Rapid reverse transcriptase polymerase 
chain reaction assessment of lymph nodes may pro-
vide immediate information regarding the status of 
the sentinel node [34]. This seems to be a promising 
technique to provide immediate diagnosis with much 
greater accuracy as compared with frozen section. The 
authors conclude that SLNB can be used safely and 
with technical success for accessible squamous cell 
carcinomas of the head and neck. It offers the potential 
for more anatomically accurate surgery based on each 
patient’s unique lymphatic drainage system. However, 
without completion of the selective neck dissection, 
there may be up to 5% chance of missing cancer in 
this group of potentially curable patients. 
Neck dissection
Neck dissection is one of the most commonly performed 
operations in head and neck surgery. Better under-
standing of the structure and pattern of lymphatic flow 
in the neck has transformed this operation into a more 
selective and less morbid treatment. Givi and Ander-
sen [35] in an excellent article entitled “Rational for 
Modifying Neck Dissection” begin by stating that neck 
dissection is one of the “most time honored operations 
in the field of head and neck surgery.” The evolution of 
this operation follows the evolution of cancer treatment 
from the first published articles in the middle of the 
19th Century [36]. The radical neck dissection included 
removal of most of the structures of the neck, including 
the spinal accessory nerve, and although the radical 
neck dissection was an effective oncologic procedure, 
it carried with it substantial morbidity which led later 
surgeons to search for operations that were the onco-
logic equivalent, but less morbid. Suarez [37] was a 
pioneer in functional neck dissection which preserved 
the nonlymphatic structures of the neck normally 
removed during a radical neck dissection. 
Radical neck dissection is defined as the removal 
of all ipsilateral cervical lymph node groups extending 
from the inferior border of the mandible to the clavicle 
and from the midline to the anterior border of the tra-
pezius muscle and included the spinal accessory nerve, 
internal jugular vein and sternocleidomastoid muscle. 
Modified radical neck dissection refers to the excision of 
all lymph nodes routinely removed by radical neck dis-
section with preservation of one or more nonlymphatic 
structures, such as: the spinal accessory nerve, internal 
jugular vein, and sternocleidomastoid muscle. Selective 
neck dissection refers to a cervical lymphadenectomy in 
which one or more of the lymph node groups are removed 
with the other structures in the neck are preserved. 
The lymph node groups that are removed are based on 
the pattern of metastasis which is predictable relative 
to the primary site of the disease. 
Neck dissection is performed in several distinct 
settings:
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– At the time of surgical treatment of a primary 
tumor without any evidence of neck metastasis (No).
– As a therapeutic modality for positive cervical 
lymph nodes with or without adjuvant chemotherapy 
(N+).
– Planned neck dissection after primary chemo-
radiation.
– As an adjunct or salvage therapy after recurrence 
or failure of primary chemoradiation.
In performing selective neck dissection (SNC) in the 
N0 neck one must consider which patient will benefit in 
terms of regional control and whether there is a survival 
benefit associated with the procedure. There are three 
randomized studies on this subject and only one which 
showed improved survival. Andersen [38] states that it 
might be “assumed that if the neck is closely observed 
instead of operated that any metastatic disease that 
occurs will be detected in an early stage. However, this 
study proved this assumption incorrect and reported 
a series of 47 patients who failed in the neck during 
the observation period. In these patients, 60% were 
pathologically N2 or greater and extracapsular spread 
was present in 50% when the failure was detected. 
This paper is widely cited as an argument for elective 
neck dissection.
The most recent step was to extend the concept of 
SND to the clinically node positive neck. This remains 
somewhat controversial, but many series, particularly 
Byers [39] whose series consisted of 967 patients , show 
that SND in early stage metastatic cancer will provide 
results comparable to modified neck dissection if fol-
lowed by adjuvant radiation therapy. 
Andersen et al [40] published results of a multi-
institutional study which showed that in a carefully 
selected group of patients it is possible to achieve good 
results with SND in the N2 neck. Their regional con-
trol rate was 94.3% in their cohort of 106 previously 
untreated patients. Andersen concludes that there is 
an expanded role for SND in the treatment of the node 
positive neck. 
One of the most highly debated topics in recent 
years has been the role of neck dissection following 
definitive chemoradiation. There are two situations 
in which neck dissection is being used. The first is 
the planned neck dissection for patients with N2-N3 
following chemoradiation without any evidence of per-
sistent or recurrent cervical metastasis. The second 
situation is in the presence of cervical metastasis, 
residual or recurrent following definitive chemora-
diation. Decision making in this situation has been 
helped tremendously by the use of PET CT scanning. 
This modality has shown a high sensitivity and high 
negative predictive value. Currently it seems that it is 
most helpful to patients who are PET negative. In this 
setting patients’ who have evidence of cancer of the 
neck on physical examination and are PET negative, 
are now followed with serial physical examination and 
PET CT scanning and it has been concluded that in the 
face of complete response and negative PET scan no 
neck dissection need be done [40]. If there is evidence 
of metastasis after chemoradiation either on physical 
examination or PET scanning then neck dissection 
may be indicated. 
A report from Vedrine et al [41] of the GETTEC group 
raises a question about the need for neck dissection 
following definitive chemoradiation. The study had a 
total of 103 patients with unresectable cancer of the 
head and neck, cervical metastasis and no distant 
metastasis who were treated between 1996 and 2002. 
After a CT scan with/without cervical ultrasound or 
PET CT demonstrated complete disappearance of neck 
nodes three months after completion of chemoradia-
tion, no neck dissections were necessary. Based on 
their five year observations the authors concluded that 
careful followup of patients is becoming the most com-
mon attitude in France thereby replacing the planned 
neck dissection. 
Lango et al [42] examined the medical records of 
65 patients who had received chemoradiation with a 
median follow up of 33 months. The recurrence free 
survival of patients with a single positive node within 
a clinically involved nodal level approached that of 
patients with a complete pathological response. It had 
been their practice to perform a comprehensive neck 
dissection at levels 1 through 4 regardless of clinical 
response to nonsurgical treatment. In this study no 
patient classified as N1-2a who underwent a compre-
hensive neck dissection was found to have residual 
cancer and no patient failed in the neck. Other inves-
tigators have suggested that a limited or SND may be 
used to treat patients with N1-2A disease. 
van der Putten et al [43], of the Netherlands Cancer 
Center and the University Medical Center, studied a 
series of 207 patients who were treated with intra-
arterial chemoradiation. The schedule consisting of 4 
consecutive weekly selective intra-arterial infusions of 
cisplatinum was followed by intravenous sodium thio-
sulfate and simultaneous radiation therapy according 
to the RADPlat protocol. Following this treatment, all 
patients with persistent or recurrent lymph node me-
tastasis and who were considered operable underwent 
a neck dissection. The median followup was 18 months 
with a range of 0 to 98 months. Based on the neck dis-
sections that were carried out, the authors conclude 
because of the good regional control rate and the high 
rate of unnecessary neck dissections with the planned 
neck dissection strategy, that a careful watch and wait 
strategy is safe. Regarding overall survival, patients 
without recurrent disease seemed to benefit more from 
this strategy than patients with residual disease. 
Mukhija et al [44] studied the issue of SND follow-
ing adjuvant therapy for advanced cancer of the head 
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and neck. The authors state that in the past surgeons 
believed that in order to eradicate regional disease, a 
radical or modified radical neck dissection was nec-
essary. An evolution in surgical principles and the 
popularization of primary chemoradiation has raised 
the question regarding the role and the extent of neck 
dissection following chemoradiotherapy. The aim of 
their study was to determine the efficacy of SND for 
patients with N2 or N3 following treatment with pri-
mary radiation or chemoradiation. They carried out 
a retrospective review of 58 patients with Stage III or 
Stage IV head and neck squamous cell carcinoma. They 
concluded that the rate of regional recurrence follow-
ing SND is similar to rates reported following radical 
or modified neck dissection and suggested that SND 
provides an appropriate surgical option for advanced 
neck disease or selected patients following adjuvant 
therapy. They state that combined chemoradiation is 
often successful in eradicating low volume neck me-
tastasis. However, the role of the neck dissection as a 
planned procedure for high volume disease in N2 and 
N3 has become controversial. The authors quote an 
article by Sewall et al [45] who examined the incidence 
of regional and distant control as well as overall sur-
vival of the patients treated with SND and compared 
these outcomes with patients who had undergone a 
comprehensive neck dissection. They found that the 
regional control, distant control and overall survival 
rate were not different with patients undergoing a SND 
or comprehensive neck dissection.
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